Sanofi's Sarclisa gets approved as a first-line option for some patients newly diagnosed with multiple myeloma
Despite largely exiting oncology, Sanofi continues to reap the benefit of its multiple myeloma treatment Sarclisa.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
